Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
暂无分享,去创建一个
Tobias Karlberg | Martin Moche | Ann-Gerd Thorsell | Herwig Schüler | Michael S. Cohen | T. Ekblad | H. Schüler | A. Thorsell | T. Karlberg | Lionel Trésaugues | M. Löw | A. F. Pinto | L. Trésaugues | M. Moche | Torun Ekblad | Michael S Cohen | Ana Filipa Pinto | Mirjam Löw | A. Pinto
[1] Giulio Draetta,et al. Oncology drug discovery: planning a turnaround. , 2014, Cancer discovery.
[2] D. Chin,et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. , 2012, Journal of medicinal chemistry.
[3] A. Ashworth,et al. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.
[4] D. Ferraris,et al. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. , 2010, Journal of medicinal chemistry.
[5] Antonella Isacchi,et al. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. , 2015, Journal of medicinal chemistry.
[6] Y. Pommier,et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.
[7] J. Weigelt,et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. , 2009, Journal of medicinal chemistry.
[8] Mo Li,et al. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. , 2013, Cancer cell.
[9] M. D. Lloyd,et al. 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). , 2011, Journal of medicinal chemistry.
[10] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[11] Martin Hammarström,et al. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. , 2010, Biochemistry.
[12] A. Harris,et al. Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.
[13] L. Lehtiö,et al. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors. , 2014, ACS medicinal chemistry letters.
[14] A. Ashworth,et al. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family , 2012, Nature Reviews Drug Discovery.
[15] D. Litchfield,et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. , 2008, Molecular cell.
[16] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[17] A Rod Merrill,et al. Structure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosa. , 2005, The Biochemical journal.
[18] J. Pascal,et al. A Third Zinc-binding Domain of Human Poly(ADP-ribose) Polymerase-1 Coordinates DNA-dependent Enzyme Activation* , 2008, Journal of Biological Chemistry.
[19] P. Nordlund,et al. Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.
[20] J. Pascal,et al. Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1 , 2012, Science.
[21] N. Curtin,et al. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. , 2013, Molecular aspects of medicine.
[22] J. Pascal,et al. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1 , 2015, Molecular cell.
[23] M. Endres,et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. , 2001, International journal of molecular medicine.
[24] A. Lau,et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.
[25] F. Apiou,et al. PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase* , 1999, The Journal of Biological Chemistry.
[26] B. Lüscher,et al. Function and regulation of the mono-ADP-ribosyltransferase ARTD10. , 2015, Current topics in microbiology and immunology.
[27] C. Koch,et al. The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair , 2013, Nucleic acids research.
[28] S. Papa,et al. JNK signalling in cancer: in need of new, smarter therapeutic targets , 2014, British journal of pharmacology.
[29] Atwood K Cheung,et al. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. , 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.
[30] C. D. Andersson,et al. Structural Basis for Lack of ADP-ribosyltransferase Activity in Poly(ADP-ribose) Polymerase-13/Zinc Finger Antiviral Protein* , 2015, The Journal of Biological Chemistry.
[31] A. Chiarugi,et al. Selective PARP‐2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post‐ischaemic brain damage , 2009, British journal of pharmacology.
[32] G. Drewes,et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.
[33] M. Micaroni,et al. PARP16/ARTD15 Is a Novel Endoplasmic-Reticulum-Associated Mono-ADP-Ribosyltransferase That Interacts with, and Modifies Karyopherin-ß1 , 2012, PloS one.
[34] Michael Krug,et al. XDSAPP: a graphical user interface for the convenient processing of diffraction data using XDS , 2012 .
[35] M. Rubin,et al. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. , 2015, Molecular cell.
[36] Xiaoguang Chen,et al. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors. , 2015, Bioorganic & medicinal chemistry.
[37] P. Nordlund,et al. The cellular thermal shift assay for evaluating drug target interactions in cells , 2014, Nature Protocols.
[38] J. Pascal,et al. Purification of human PARP-1 and PARP-1 domains from Escherichia coli for structural and biochemical analysis. , 2011, Methods in molecular biology.
[39] Liang Zhao,et al. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.
[40] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[41] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[42] L. Lehtiö,et al. Structural basis of selective inhibition of human tankyrases. , 2012, Journal of medicinal chemistry.
[43] G. Schulz,et al. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[44] G. Murcia,et al. Identification of potential active-site residues in the human poly(ADP-ribose) polymerase. , 1993, The Journal of biological chemistry.
[45] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .
[46] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[47] J. Ledermann,et al. PARP inhibitors in ovarian cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] S. Kazmirski,et al. Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology. , 2015, ACS medicinal chemistry letters.
[49] H. Schüler,et al. Crystal Structure of Human ADP-ribose Transferase ARTD15/PARP16 Reveals a Novel Putative Regulatory Domain* , 2012, The Journal of Biological Chemistry.
[50] S. Krauss,et al. Tankyrases as drug targets , 2013, The FEBS journal.
[51] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[52] G. Schulz,et al. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. , 1998, Journal of molecular biology.
[53] S. Krauss,et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.
[54] Emidio Camaioni,et al. PARP inhibitors: polypharmacology versus selective inhibition , 2013, The FEBS journal.
[55] M. O’Connor,et al. Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.
[56] P. Fitzpatrick,et al. Structural Biology Communications Structural Basis for the Inhibition of Poly(adp- Ribose) Polymerases 1 and 2 by Bmn 673, a Potent Inhibitor Derived from Dihydropyridophthalazinone , 2022 .
[57] Manash S. Chatterjee,et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 2013, The Lancet. Oncology.
[58] J. Weigelt,et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.
[59] G. Schulz,et al. Photoaffinity labelling of human poly(ADP-ribose) polymerase catalytic domain. , 1997, The Biochemical journal.
[60] Lawrence Lum,et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.
[61] Natalia Markova,et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. , 2010, Journal of medicinal chemistry.
[62] Eric F. Johnson,et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. , 2009, Journal of medicinal chemistry.
[63] F. Bock,et al. Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer. , 2015, Trends in molecular medicine.
[64] P. Hassa,et al. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review , 2015, Molecular Cancer.
[65] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[66] V. Schreiber,et al. PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways , 2014, Nucleic acids research.
[67] A. Montagnoli,et al. Insights into PARP Inhibitors’ Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays , 2014, Journal of biomolecular screening.